On 14th November 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency announced their positive opinion on the marketing authorisation of lecanemab (monoclonal anti-beta-amyloid antibody; trade name: Leqembi from Eisai and Biogen) in the European Union for the treatment of early Alzheimer’s disease in Europe. In 2023, the drug […]
EUROIMMUN chemiluminescence immunoassays (ChLIA) for Alzheimer’s disease (AD) biomarkers provide reliable analytical and clinical performance, as demonstrated in two newly published studies performed in a collaboration between researchers at EUROIMMUN and the Memory Clinic of the University Hospital Magdeburg, Germany. Measurement of the four core biomarkers beta-amyloid (Aβ) 1-40, Aβ1-42, total tau and tau phosphorylated
The number of registered whooping cough cases this year is much higher than it was at the same time last year. After a longer break due to the COVID protection measures, case numbers now return to their pre-pandemic levels in many countries. In Germany, another temporary trend was observed: For 2022/2023 the Robert-Koch-Institut (RKI) notes
It is easy to tell that this year‘s cold season, which started at the end of summer with a relatively high number of infections, is now fully on: runny noses, cough, etc. are bringing more and more patients: Runny noses, cough, etc. are bringing more and more patients into the doctor’s practices, as did the
With passion for rheumatology! Autoantibody testing is becoming increasingly important in rheumatological diagnostics. It delivers crucial information for differential diagnostics and sometimes even allows prediction of the disease progression or helps in the choice of therapy. Before diagnostic use, all serological tests undergo thorough investigation. They are only approved when they meet the respective criteria.
